

1 **Title**

2 Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients

3

4

5 **Authors**

6 Xiaoping Chen¹, Wenjia Hu¹, Jiabin Ling², Pingzheng Mo¹, Yongxi Zhang¹, Qunqun Jiang¹,
7 Zhiyong Ma¹, Qian Cao¹, Liping Deng¹, Shihui Song¹, Ruiying Zheng¹, Shicheng Gao¹,
8 Hengning Ke¹, Xien Gui¹, Åke Lundkvist², Jinlin Li³, Johanna F Lindahl^{2,4,5}, Yong Xiong¹

9

10

11 ***Corresponding authors**

12 Yong Xiong (yongxiong64@163.com)

13 Johanna F Lindahl (johanna.lindahl@imbim.uu.se)

14 Jinlin Li (jinlin.li@ki.se)

15

16

17 **Author affiliations**

18 1 Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, No.169,
19 Donghu Road, Wuchang District, 430071 Wuhan, Hubei Province, China

20 2 Department of Medical Biochemistry and Microbiology, Zoonosis Science Center,
21 University of Uppsala, Uppsala, Sweden

22 3 Department of Cell and Molecular Biology, Karolinska Institutet, 171 65, Stockholm
23 Sweden

24 4 Department of Biosciences, International Livestock Research Institute, 100000 Hanoi,
25 Vietnam

26 5 Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala,
27 Sweden

28

29 Abstract = 186 words, Main text = 1722 words, Figures =2.

30 **Abstract**

31 Objectives: Comorbidities have significant indications for the disease outcome of COVID-19,
32 however which underlying diseases that contribute the most to aggravate the conditions of
33 COVID-19 patients is still largely unknown. SARS-CoV-2 viral clearance is a golden standard
34 for defining the recovery of COVID-19 infections. To dissect the underlying diseases that
35 could impact on viral clearance, we enrolled 106 COVID-19 patients who were hospitalized in
36 the Zhongnan Hospital of Wuhan University, Wuhan, China between Jan 5 and Feb 25,
37 2020.

38 Methodology: We comprehensively analyzed demographic, clinical and laboratory data, as
39 well as patient treatment records. Survival analyses with Kaplan-Meier and Cox regression
40 modelling were employed to identify factors influencing the viral clearance negatively.

41 Results: We found that increasing age, male gender, and angiotensin-converting enzyme 2
42 (ACE2) associated factors (including hypertension, diabetes, and cardiovascular diseases)
43 adversely affected the viral clearance. Furthermore, analysis by a random forest survival
44 model pointed out hypertension, cortisone treatment, gender, and age as the four most
45 important variables.

46 Conclusions: We conclude that patients at old age, males, and/or having diseases
47 associated with high expression of ACE2 will have worse prognosis during a COVID-19
48 infections.

49

50 **Keywords.** COVID-19; SARS-CoV-2; Comorbidities; Risk factors; ACE2.

51 **Introduction**

52 Emerging infectious diseases (EID) in both animals and humans cause major economic and
53 health burden globally and around 75% of all EIDs are zoonotic, of which many originate
54 from wildlife [1]. There has been an estimate that a new human disease appears every four

55 months, driven by mainly anthropogenic changes, including land-use change (deforestation,
56 irrigation, urbanization), climate change, population growth, and globalization [1, 2]. The most
57 noteworthy and important EIDs during this millennium belong to the genus coronavirus (CoV),
58 a group of enveloped, single-stranded, positive-sense RNA viruses. In 2002-03, an outbreak
59 of severe acute respiratory syndrome (SARS), caused by a coronavirus later termed SARS-
60 CoV, started out of China. This was followed by the spread of Middle East respiratory
61 syndrome coronavirus (MERS-CoV) in 2012. In 2019, a new pandemic started out of China,
62 COVID-19, caused by SARS-CoV-2 [3-5]. The origins of these zoonotic viruses seem to be
63 bats, which have been shown to harbor many different coronaviruses [6-8], even though it
64 seems necessary with an amplifying host closer to humans to obtain a species jump to man.
65 For MERS-CoV, the main amplifying host close to humans has been identified as
66 dromedaries, while for SARS-CoV-2, the amplifiers were likely small mammals sold at live
67 animal markets [3–5]. Cross-species transmission and the ability to sustain many cycles of
68 human-to human transmission requires a solid interaction between the receptor-binding viral
69 proteins and receptors on the host cells [9]. The host cell receptor for SARS-CoV and SARS-
70 CoV-2 seems to be the angiotensin-converting enzyme 2 (ACE2) enzyme, presented on
71 many epithelial cells in the respiratory tract [10-12].

72 COVID-19 most often displays as fever, cough and mild fatigue, sometimes also dyspnea,
73 myalgia and severe anorexia, and may develop into critical respiratory failure that sometimes
74 becomes fatal [13-16]. In one study, mild cases seemed to account for 81%, while another
75 study found at least 50% of the infected were asymptomatic, but transmission can occur from
76 both symptomatic and asymptomatic carriers [15, 17, 18]. As compared to SARS-CoV with a
77 reproductive number (R_0) of 2-5 [19, 20] and R_0 of MERS-CoV from 0.6 to 3 [21], it seems
78 that SARS-CoV-2 is likely having an R_0 in the range of 2-3 [20], but the new virus has
79 already killed more people due to its global spread [22].

80

81

82 According to the clinical characteristics, It has been shown that severe COVID-19 often
83 occurred in patients with diabetes, hypertension or other comorbidities [11]. In COVID-19
84 patients with underlying diseases, a very high case fatality rate (73.3%) has been observed
85 [23]. However, how these comorbidities affect the COVID-19 prognosis is not yet understood.
86 Potential factors might be that these comorbidities directly accelerate the damage of target
87 tissues or that they favour the virus life-cycle during a SARS-CoV-2 infection. Trying to
88 answer this critical and complex question, we analyzed data from COVID-19 hospitalized
89 patients and evaluated which underlying diseases that had the highest risk to aggravate the
90 conditions of a COVID-19 infection. We found that chronic diseases including diabetes and
91 hypertension deteriorate the clearance of SARS-CoV-2.

92

93 **Methods**

94 Between Jan 5 and Feb 25, 2020, we collected the records of 106 hospitalized patients,
95 whose throat-swab specimens had been tested positive for SARS-CoV-2 by qRT-PCR on
96 admission according to a protocol previously described [13]. The patients who repeatedly
97 tested SARS-CoV-2 RNA negative for at least two times with an interval of at least one day
98 were regarded as viral negative. The admission date was used as the starting time-point for
99 the viral clearance process, and the date of the second negative detection of viral RNA was
100 calculated as the end time-point of viral clearance. We recorded patient demographic data
101 including gender, age and lag time from onset of disease until seeking hospital care (lag
102 time); clinical data of chronic diseases including hypertension, chronic obstructive pulmonary
103 disease (COPD), gender, age, liver disease, cancer, cardiovascular diseases and diabetes
104 existed as comorbidities; treatment data including usage of antivirals or cortisone. The data
105 were imported and analyzed using R language, implemented in RStudio [24, 25]. Package
106 survival, survminer, ranger and ggplot2 were employed for survival analysis, modelling and

107 visualization separately [26-30]. Informed consents were obtained from all patients upon
108 admission to the Department of Infectious Diseases, Zhongnan Hospital of Wuhan
109 University, Wuhan, China. This study was approved by the ethics board in Zhongnan
110 Hospital of Wuhan University, Wuhan, China (No.2020011).

111 **Results**

112 In a total of 106 patients, 63 females (63/106, 59.4%) and 43 males (43/106, 40.6%), were
113 included in the study. The days of observation spanned from 4 days to 37 days. On day 37,
114 99 patients had cleared the virus infection and 5 had died (4.7%, 95% confidence interval
115 1.5-10.7%). The age of the patients spanned from 20 to 96 years with an average of 50.9
116 years (25%–75% interquartile range (IQR), 35.0 – 64.6 years). Underlying diseases included
117 17 patients with hypertension (16.0%), six with cardiovascular disease (5.7%), nine with
118 diabetes (8.5%), two with malignancy (1.9%) and 10 with chronic liver disease (9.4%).
119 Antivirals and cortisone had been used in 67 (63.2%) and 54 (50.9%) of the patients,
120 respectively.

121 We monitored the time until viral clearance during the clinical course of the patients. The
122 patients had a median time of 15 days (IQR, 10 – 20 days) until negative of SARS-CoV-2
123 viral RNA. The overall viral clearance events by using Kaplan-Meier survival analysis are
124 summarized in Figure. Over 80% patients reached viral clearance (qRT-PCR was negative
125 for SARS-CoV-2) within 25 days from the first day of laboratory-confirmed SARS-CoV-2
126 infection.

127 In another Cox proportional hazards model, we included the demographic, clinical, and
128 treatment variables to model the risk factors for viral positivity over time. We found
129 hypertension ($P=0.01$) and corticosteroid treatment ($P=0.03$) to be risk factors preventing
130 viral clearance. To better observe the contribution of each variable to the Cox model over
131 time, Aalen's additive regression model was used to plot the additive coefficient of each
132 variable over the time. Within the first five days of the viral clearance process, no variable

133 had any effect on the model (coefficient fluctuates around 0). With longer time of observation
134 (from day 5 to day 20), COPD, age, carcinoma, corticosteroid treatment, diabetes, gender,
135 hypertension, and lag time had negative effects (coefficient < 0) on the model, suggesting
136 that if patients had those factors, the time of viral clearance were prolonged. However, the
137 interval of additive coefficient increased over time, suggesting that an uncertainty of each
138 variable's contribution to the model is increased due to a reduced number of patients
139 remaining in the model.

140 Finally, a random forest survival model was used to analyze which variables explained
141 SARS-CoV-2 viral positivity. We found that hypertension (index=0.0353), the usage of
142 cortisone (index=0.0265), gender (index=0.0221), and age (index=0.0076) were the top four
143 important variables. By examining the vibration of the risks function over time, three survival
144 models: Kaplan-Meier, Aalen's additive regression model and random forest survival model
145 were used to model when the patients become clear from the viral infections. Interestingly,
146 we found hypertension (in three models), treatment with cortisone (in three models),
147 increasing age (in the random forest survival model), and male gender (in the random forest
148 survival model) had negative effects on the viral clearance in COVID-19 patients.

149 **Discussion**

150 Our analyses pinpointed hypertension as the most important risk factor and this has been
151 suggested by other studies as well [11, 23]. Hypertension, diabetes, and cardiovascular
152 diseases are associated with abnormal regulation of renin-angiotensin system (RAS) and
153 ACE2 has a key role involved in this process [11]. It is likely that the patients with these
154 comorbidities had been treated with ACE2 inhibitors, which could have affected the presence
155 of these receptors, increasing the receptor usage of SARS-CoV-2 [10]. Other studies have
156 showed that high expression of ACE2 in the patients with hypertension, diabetes, and
157 cardiovascular diseases might facilitate SARS-CoV-2 to enter the targeted cells in the
158 respiratory system, and prolong the time of viral clearance [11, 31]. On the other hand, old

159 people usually have a high risk of in hypertension, diabetes, and cardiovascular diseases
160 [32], making age and these diseases difficult to discern.

161 Sex, age and immunity are notable biological factors during combating infectious pathogens
162 [33]. In our model, male and old age were also identified as risk factors. The immune system
163 is different between females and males [34]. Females may have lower susceptibility to viral
164 infections, because estrogen and progesterone can help to increase the innate and adaptive
165 immune responses, and many immune genes are X-linked [35]. High immune reactivity post
166 viral infection in women can accelerate the process of viral clearance but, on the other hand,
167 could be leading to immune-pathogenicity and autoimmunity. Gender differences can also
168 affect risk factors, with men e.g. being more likely to develop hypertension [36]. Males have a
169 high ratio of hypertension in mice models due to decreased adipose ACE2 activity [37].
170 However, although the ACE2 gene is located in the X chromosome, there is no evidence of
171 different expression of ACE2 between the sexes [38].

172 Until now, there is no effective medicine available to treat COVID-19. Accordingly, the usage
173 of antivirals (Arbidol) had no effect on the viral clearance, according to our results. The usage
174 of cortisone had unexpectedly a negative effect on the process of viral clearance, although
175 cortisone was commonly used in the SARS patients [39]. However, it is possible that
176 cortisone was targeted at particularly severe cases, which may have confounded the results.
177 Compared to SARS, the outcome of using corticosteroids in COVID-19 patients is still
178 unclear [14, 40]. Given that corticosteroids as immune-modulators that can decline
179 circulating specific B- and T-cell subsets [41] and our modelling, the usage of cortisone
180 would not be recommended.

181 In conclusion, patients with hypertension, male and old age have increased risk for late viral
182 clearance of the virus, and thus worsened prognosis in COVID-19 infections, likely due to the
183 fact that those risk factors are associated with high expression of ACE2. The usage of ACE2
184 inhibitors for patients with hypertension, diabetes, and CVD need to be carefully considered.

185 It is recommended that future projects not only collect data on comorbidities, but also
186 compare the risk for patients with the same disease in regards to the medications they were
187 taking before the infection by SARS-CoV-2. The general profile of hazards in COVID-19
188 hospitalized patients over time could provide us more information in the decision-making and
189 personalized treatment during the clinical practice.

190

191 **Acknowledgements**

192 This study was funded by the Zhongnan Hospital of Wuhan University, Science, Technology
193 and Innovation Seed Fund, grant number znp2018007 and the Swedish Research Council,
194 grant number 2017-05807. The funders had no role in study design, data collection or
195 analysis, decision to publish or preparation of the manuscript. The authors declared no
196 competing interests.

197

198 **Figure legends**

199 **Figure 1.** Kaplan-Meier estimates of SARS-CoV-2 viral clearance rate over time.

200 **Figure 2.** Aalen's additive regression model of each covariant over time. Covariants included
201 gender, age, lag time, hypertension, COPD, liver diseases, diabetes, CVD, cancer, antivirals
202 and corticosteroids as treatment.

203

204 **Reference:**

205


- 206 1. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends
207 in emerging infectious diseases. *Nature*. 2008; 451(7181): 990-3.
- 208 2. Lindahl JF, Grace D. The consequences of human actions on risks for infectious
209 diseases: a review. *Infect Ecol Epidemiol*. 2015; 5: 30048.
- 210 3. Guarner J. Three Emerging Coronaviruses in Two Decades. *Am J Clin Pathol*. 2020;
211 153(4): 420-1.

- 212 4. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent
213 insights into emerging coronaviruses. *Nat Rev Microbiol.* 2016; 14(8): 523-34.
- 214 5. Hilgenfeld R, Peiris M. From SARS to MERS: 10 years of research on highly
215 pathogenic human coronaviruses. *Antiviral Res.* 2013; 100(1): 286-95.
- 216 6. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of
217 SARS-like coronaviruses. *Science.* 2005; 310(5748): 676-9.
- 218 7. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory
219 syndrome coronavirus-like virus in Chinese horseshoe bats. *Proc Natl Acad Sci U S A.*
220 2005; 102(39): 14040-5.
- 221 8. Tong S, Conrardy C, Ruone S, Kuzmin IV, Guo X, Tao Y, et al. Detection of novel
222 SARS-like and other coronaviruses in bats from Kenya. *Emerg Infect Dis.* 2009; 15(3):
223 482-5.
- 224 9. Li W, Hulswit RJG, Kenney SP, Widjaja I, Jung K, Alhamo MA, et al. Broad receptor
225 engagement of an emerging global coronavirus may potentiate its diverse cross-
226 species transmissibility. *Proc Natl Acad Sci U S A.* 2018; 115(22): E5135-E43.
- 227 10. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus
228 from Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol.*
229 2020;10.1128/JVI.00127-20.
- 230 11. Fang LK, G.; Roth, M. . Are patients with hypertension and diabetes mellitus at
231 increased risk for COVID-19 infection? *Lancet Respir. Med.* 2020. 2020.
- 232 12. Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining 'host jump' of
233 coronaviruses SARS-CoV, MERS-CoV, and beyond. *Trends Microbiol.* 2015; 23(8):
234 468-78.
- 235 13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
236 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
237 China. *JAMA.* 2020;10.1001/jama.2020.1585.
- 238 14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
239 infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020; 395(10223):
240 497-506.
- 241 15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
242 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases
243 From the Chinese Center for Disease Control and Prevention. *JAMA.*
244 2020;10.1001/jama.2020.2648.
- 245 16. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
246 Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.*
247 2020;10.1056/NEJMoa2001316.
- 248 17. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier
249 Transmission of COVID-19. *JAMA.* 2020;10.1001/jama.2020.2565.
- 250 18. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
251 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
252 Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill.* 2020; 25(10).
- 253 19. Bauch CT, Lloyd-Smith JO, Coffee MP, Galvani AP. Dynamically modeling SARS and
254 other newly emerging respiratory illnesses: past, present, and future. *Epidemiology.*
255 2005; 16(6): 791-801.
- 256 20. Liu YGW-S. The reproductive number of COVID-19 is higher compared to SARS
257 coronavirus. diva-portal.org.
- 258 21. Cauchemez S, Van Kerkhove MD, Riley S, Donnelly CA, Fraser C, Ferguson NM.
259 Transmission scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-
260 CoV) and how to tell them apart. *Euro Surveill.* 2013; 18(24).
- 261 22. Mahase E. Coronavirus covid-19 has killed more people than SARS and MERS
262 combined, despite lower case fatality rate. *BMJ* 2020, 368, m641.


- 263 23. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
264 Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;10.1056/NEJMoa2002032.
- 265 24. Team RC. R: A language and environment for statistical computing. R Foundation for
266 Statistical Computing, Vienna, Austria. URL <http://www.r-project.org/>. 3.6.3 ed, 2020.
- 267 25. Team. R. RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL
268 <http://www.rstudio.com/>. Version 1.1.453 ed, 2015.
- 269 26. Kassambara AK, M.; Biecek, P.; Fabian, S.. Package 'survminer' Drawing Survival
270 Curves using 'ggplot2'. 2019-09-03 ed,
271 <http://www.sthda.com/english/rpkgs/survminer/>, 2019.
- 272 27. Terry MTT, L.; Atkinson, E.; Crowson, C.. Package 'survival': Survival Analysis.
273 <https://github.com/therneau/survival>, 2019.
- 274 28. Wright NMW, S.; Probst, P.. Package 'ranger':A Fast Implementation of Random
275 Forests. <https://github.com/imbs-hl/ranger>, 2020.
- 276 29. Wickham H. ggplot2: elegant graphics for data analysis. Springer New York., 2009.
- 277 30. Rickert J. Survival Analysis with R. R Views,
278 <https://rviews.rstudio.com/2017/09/25/survival-analysis-with-r/>, 2017.
- 279 31. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system:
280 Physiological relevance and therapeutic implications in cardiovascular, hypertensive
281 and kidney diseases. *Pharmacol Res*. 2017; 125(Pt A): 21-38.
- 282 32. Rådholm K. Cardiovascular risk factors in elderly With special emphasis on atrial
283 fibrillation, hypertension and diabetes.: Linköping University, 2015.
- 284 33. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;
285 16(10): 626-38.
- 286 34. Taneja V. Sex Hormones Determine Immune Response. *Front Immunol*. 2018; 9:
287 1931.
- 288 35. Ghosh S, Klein RS. Sex Drives Dimorphic Immune Responses to Viral Infections. *J*
289 *Immunol*. 2017; 198(5): 1782-90.
- 290 36. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al.
291 Residual lifetime risk for developing hypertension in middle-aged women and men:
292 The Framingham Heart Study. *JAMA*. 2002; 287(8): 1003-10.
- 293 37. Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K. Role of angiotensin-converting
294 enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in
295 renal wrap hypertension in rats. *Exp Physiol*. 2008; 93(5): 648-57.
- 296 38. AISiraj YW, C.; Thatcher, E. S.; Cassia, A. L., . Chapter 11 - Sex Differences and the
297 Role of the Renin-Angiotensin System in Atherosclerosis and Abdominal Aortic
298 Aneurysms. *Sex Differences in Cardiovascular Physiology and Pathophysiology:*
299 Academic press, 2019.
- 300 39. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects.
301 *PLoS Med*. 2006; 3(9): e343.
- 302 40. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of
303 COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*.
304 2020;10.1016/S2213-2600(20)30076-X.
- 305 41. Olnes MJ, Kotliarov Y, Biancotto A, Cheung F, Chen J, Shi R, et al. Effects of
306 Systemically Administered Hydrocortisone on the Human Immunome. *Sci Rep*. 2016;
307 6: 23002.

308

medRxiv preprint doi: <https://doi.org/10.1101/2020.03.22.20040774>; this version posted March 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).



Number at risk (number censored)



Strata + All

additive coefficient vs. day

medRxiv preprint doi: <https://doi.org/10.1101/2020.03.22.20040774>; this version posted March 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

